{"nctId":"NCT00932646","briefTitle":"Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease","startDateStruct":{"date":"2009-06"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":100,"armGroups":[{"label":"BI1744 (Olodaterol)","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1744 (Olodaterol) Medium Dose"]},{"label":"BI 1744 (Olodaterol)","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1744 (Olodaterol) Low Dose"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Foradil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Foradil"]}],"interventions":[{"name":"BI 1744 (Olodaterol) Low Dose","otherNames":[]},{"name":"BI 1744 (Olodaterol) Medium Dose","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Foradil","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients willing to participate with confirmed diagnosis of COPD\n* 40 years of age or older\n* having a 10 pack year smoking history\n* able to perform serial pulmonary function tests\n* able to use both a DPI and Respimat device\n\nExclusion Criteria:\n\nSignificant other disease\n\n* clinically relevant abnormal hematology, chemistry, or urinalysis\n* history of asthma\n* diagnosis of thyrotoxicosis\n* paroxysmal tachycardia related to beta agonists\n* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year\n* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis\n* significant alcohol or drug use\n* pulmonary resection\n* taking oral beta adrenergics\n* taking unstable oral steroids\n* daytime oxygen\n* enrolled in rehabilitation program\n* enrolled in another study or taking investigational products\n* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control\n* those who are not willing to comply with pulmonary medication washouts","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.022","spread":"0.024"},{"groupId":"OG001","value":"0.150","spread":"0.024"},{"groupId":"OG002","value":"0.152","spread":"0.024"},{"groupId":"OG003","value":"0.136","spread":"0.024"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 h (AUC 0-24h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.035","spread":"0.024"},{"groupId":"OG001","value":"0.110","spread":"0.024"},{"groupId":"OG002","value":"0.112","spread":"0.024"},{"groupId":"OG003","value":"0.121","spread":"0.024"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-3h was calculated from 0-3hours post-dose using the trapezoidal rule, divided by the observation time (3 h) to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":"0.024"},{"groupId":"OG001","value":"0.190","spread":"0.025"},{"groupId":"OG002","value":"0.202","spread":"0.025"},{"groupId":"OG003","value":"0.217","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak values were obtained within 0 - 3 hours after the last am dose after six weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":"0.026"},{"groupId":"OG001","value":"0.268","spread":"0.026"},{"groupId":"OG002","value":"0.273","spread":"0.026"},{"groupId":"OG003","value":"0.293","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.012","spread":"0.030"},{"groupId":"OG001","value":"0.109","spread":"0.030"},{"groupId":"OG002","value":"0.115","spread":"0.030"},{"groupId":"OG003","value":"0.093","spread":"0.030"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.032","spread":"0.040"},{"groupId":"OG001","value":"0.219","spread":"0.040"},{"groupId":"OG002","value":"0.214","spread":"0.040"},{"groupId":"OG003","value":"0.203","spread":"0.040"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.078","spread":"0.041"},{"groupId":"OG001","value":"0.083","spread":"0.041"},{"groupId":"OG002","value":"0.079","spread":"0.041"},{"groupId":"OG003","value":"0.144","spread":"0.041"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.055","spread":"0.039"},{"groupId":"OG001","value":"0.151","spread":"0.039"},{"groupId":"OG002","value":"0.147","spread":"0.039"},{"groupId":"OG003","value":"0.174","spread":"0.039"}]}]}]},{"type":"SECONDARY","title":"Peak FVC (0-3h) Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC was obtained within 0 - 3 hours after the last am dose of study drug after 6 weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.138","spread":"0.043"},{"groupId":"OG001","value":"0.436","spread":"0.043"},{"groupId":"OG002","value":"0.440","spread":"0.043"},{"groupId":"OG003","value":"0.475","spread":"0.043"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.007","spread":"0.053"},{"groupId":"OG001","value":"0.125","spread":"0.053"},{"groupId":"OG002","value":"0.133","spread":"0.054"},{"groupId":"OG003","value":"0.141","spread":"0.054"}]}]}]},{"type":"PRIMARY","title":"FEV1 Area Under Curve 12-24h (AUC 12-24h) Response After Six Weeks of Treatment","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.048","spread":"0.025"},{"groupId":"OG001","value":"0.069","spread":"0.025"},{"groupId":"OG002","value":"0.072","spread":"0.025"},{"groupId":"OG003","value":"0.107","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG","description":"Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":94},"commonTop":["Chronic obstructive pulmonary disease","Upper respiratory tract infection"]}}}